nodes	percent_of_prediction	percent_of_DWPC	metapath
Canagliflozin—ABCC2—epilepsy syndrome	0.179	0.57	CbGaD
Canagliflozin—ALB—epilepsy syndrome	0.069	0.22	CbGaD
Canagliflozin—ABCB1—epilepsy syndrome	0.0658	0.21	CbGaD
Canagliflozin—ABCC2—Levetiracetam—epilepsy syndrome	0.045	0.0945	CbGbCtD
Canagliflozin—UGT1A9—Propofol—epilepsy syndrome	0.0434	0.0913	CbGbCtD
Canagliflozin—UGT1A9—Valproic Acid—epilepsy syndrome	0.031	0.0652	CbGbCtD
Canagliflozin—ABCC2—Carbamazepine—epilepsy syndrome	0.0258	0.0543	CbGbCtD
Canagliflozin—ALB—Oxcarbazepine—epilepsy syndrome	0.0256	0.0539	CbGbCtD
Canagliflozin—ABCC2—Phenytoin—epilepsy syndrome	0.0232	0.0487	CbGbCtD
Canagliflozin—ALB—Fosphenytoin—epilepsy syndrome	0.0224	0.0471	CbGbCtD
Canagliflozin—ABCC2—Phenobarbital—epilepsy syndrome	0.0207	0.0434	CbGbCtD
Canagliflozin—ALB—Clonazepam—epilepsy syndrome	0.0203	0.0426	CbGbCtD
Canagliflozin—ALB—Rufinamide—epilepsy syndrome	0.0165	0.0347	CbGbCtD
Canagliflozin—ABCB1—Levetiracetam—epilepsy syndrome	0.0147	0.0308	CbGbCtD
Canagliflozin—ALB—Phenytoin—epilepsy syndrome	0.0144	0.0304	CbGbCtD
Canagliflozin—ALB—Propofol—epilepsy syndrome	0.0135	0.0283	CbGbCtD
Canagliflozin—ALB—Diazepam—epilepsy syndrome	0.0122	0.0256	CbGbCtD
Canagliflozin—ABCB1—Clobazam—epilepsy syndrome	0.0102	0.0214	CbGbCtD
Canagliflozin—ABCB1—Lamotrigine—epilepsy syndrome	0.00978	0.0206	CbGbCtD
Canagliflozin—ABCB1—Carbamazepine—epilepsy syndrome	0.00842	0.0177	CbGbCtD
Canagliflozin—CYP3A4—Oxcarbazepine—epilepsy syndrome	0.00804	0.0169	CbGbCtD
Canagliflozin—ABCB1—Phenytoin—epilepsy syndrome	0.00755	0.0159	CbGbCtD
Canagliflozin—CYP3A4—Trimethadione—epilepsy syndrome	0.00747	0.0157	CbGbCtD
Canagliflozin—CYP3A4—Felbamate—epilepsy syndrome	0.00747	0.0157	CbGbCtD
Canagliflozin—CYP3A4—Fosphenytoin—epilepsy syndrome	0.00702	0.0148	CbGbCtD
Canagliflozin—ABCB1—Phenobarbital—epilepsy syndrome	0.00673	0.0142	CbGbCtD
Canagliflozin—ABCB1—Midazolam—epilepsy syndrome	0.00664	0.014	CbGbCtD
Canagliflozin—ABCB1—Diazepam—epilepsy syndrome	0.00638	0.0134	CbGbCtD
Canagliflozin—CYP3A4—Clonazepam—epilepsy syndrome	0.00635	0.0133	CbGbCtD
Canagliflozin—CYP3A4—Clobazam—epilepsy syndrome	0.00609	0.0128	CbGbCtD
Canagliflozin—CYP3A4—Rufinamide—epilepsy syndrome	0.00518	0.0109	CbGbCtD
Canagliflozin—CYP3A4—Carbamazepine—epilepsy syndrome	0.00505	0.0106	CbGbCtD
Canagliflozin—CYP3A4—Primidone—epilepsy syndrome	0.00471	0.0099	CbGbCtD
Canagliflozin—CYP3A4—Phenytoin—epilepsy syndrome	0.00453	0.00951	CbGbCtD
Canagliflozin—CYP3A4—Propofol—epilepsy syndrome	0.00422	0.00887	CbGbCtD
Canagliflozin—CYP3A4—Phenobarbital—epilepsy syndrome	0.00403	0.00848	CbGbCtD
Canagliflozin—CYP3A4—Acetazolamide—epilepsy syndrome	0.00403	0.00848	CbGbCtD
Canagliflozin—CYP3A4—Midazolam—epilepsy syndrome	0.00398	0.00836	CbGbCtD
Canagliflozin—CYP3A4—Diazepam—epilepsy syndrome	0.00382	0.00804	CbGbCtD
Canagliflozin—CYP3A4—Zonisamide—epilepsy syndrome	0.00373	0.00784	CbGbCtD
Canagliflozin—CYP3A4—Valproic Acid—epilepsy syndrome	0.00301	0.00634	CbGbCtD
Canagliflozin—CYP3A4—Topiramate—epilepsy syndrome	0.00272	0.00572	CbGbCtD
Canagliflozin—Dapagliflozin—CYP2D6—epilepsy syndrome	0.000792	0.583	CrCbGaD
Canagliflozin—Dapagliflozin—ABCB1—epilepsy syndrome	0.000565	0.417	CrCbGaD
Canagliflozin—Fatigue—Felbamate—epilepsy syndrome	0.000114	0.000865	CcSEcCtD
Canagliflozin—Infection—Lamotrigine—epilepsy syndrome	0.000114	0.000861	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Vigabatrin—epilepsy syndrome	0.000114	0.000861	CcSEcCtD
Canagliflozin—Urethral disorder—Pregabalin—epilepsy syndrome	0.000114	0.000859	CcSEcCtD
Canagliflozin—Urticaria—Fosphenytoin—epilepsy syndrome	0.000114	0.000858	CcSEcCtD
Canagliflozin—Constipation—Felbamate—epilepsy syndrome	0.000114	0.000858	CcSEcCtD
Canagliflozin—Nausea—Lacosamide—epilepsy syndrome	0.000113	0.000856	CcSEcCtD
Canagliflozin—Shock—Lamotrigine—epilepsy syndrome	0.000113	0.000853	CcSEcCtD
Canagliflozin—Nervous system disorder—Lamotrigine—epilepsy syndrome	0.000113	0.00085	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Zonisamide—epilepsy syndrome	0.000112	0.000848	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Diazepam—epilepsy syndrome	0.000112	0.000847	CcSEcCtD
Canagliflozin—Fatigue—Zonisamide—epilepsy syndrome	0.000112	0.000846	CcSEcCtD
Canagliflozin—Malnutrition—Valproic Acid—epilepsy syndrome	0.000112	0.000844	CcSEcCtD
Canagliflozin—Constipation—Zonisamide—epilepsy syndrome	0.000111	0.00084	CcSEcCtD
Canagliflozin—Hypotension—Carbamazepine—epilepsy syndrome	0.000111	0.000838	CcSEcCtD
Canagliflozin—Urticaria—Vigabatrin—epilepsy syndrome	0.000111	0.000836	CcSEcCtD
Canagliflozin—Hypersensitivity—Midazolam—epilepsy syndrome	0.000111	0.000835	CcSEcCtD
Canagliflozin—Abdominal pain—Vigabatrin—epilepsy syndrome	0.00011	0.000832	CcSEcCtD
Canagliflozin—Nausea—Clobazam—epilepsy syndrome	0.00011	0.000831	CcSEcCtD
Canagliflozin—Asthenia—Propofol—epilepsy syndrome	0.00011	0.000831	CcSEcCtD
Canagliflozin—Pancreatitis—Topiramate—epilepsy syndrome	0.00011	0.000828	CcSEcCtD
Canagliflozin—Dizziness—Acetazolamide—epilepsy syndrome	0.000109	0.000825	CcSEcCtD
Canagliflozin—Hypersensitivity—Levetiracetam—epilepsy syndrome	0.000109	0.000824	CcSEcCtD
Canagliflozin—Urticaria—Diazepam—epilepsy syndrome	0.000109	0.000823	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Felbamate—epilepsy syndrome	0.000109	0.00082	CcSEcCtD
Canagliflozin—Pruritus—Propofol—epilepsy syndrome	0.000108	0.000819	CcSEcCtD
Canagliflozin—Abdominal pain—Diazepam—epilepsy syndrome	0.000108	0.000819	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Clonazepam—epilepsy syndrome	0.000108	0.000817	CcSEcCtD
Canagliflozin—Fatigue—Clonazepam—epilepsy syndrome	0.000108	0.000816	CcSEcCtD
Canagliflozin—Asthenia—Midazolam—epilepsy syndrome	0.000108	0.000813	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Phenytoin—epilepsy syndrome	0.000107	0.000811	CcSEcCtD
Canagliflozin—Fatigue—Phenytoin—epilepsy syndrome	0.000107	0.00081	CcSEcCtD
Canagliflozin—Constipation—Clonazepam—epilepsy syndrome	0.000107	0.000809	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Oxcarbazepine—epilepsy syndrome	0.000107	0.000807	CcSEcCtD
Canagliflozin—Fatigue—Oxcarbazepine—epilepsy syndrome	0.000107	0.000806	CcSEcCtD
Canagliflozin—Constipation—Phenytoin—epilepsy syndrome	0.000106	0.000804	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Zonisamide—epilepsy syndrome	0.000106	0.000803	CcSEcCtD
Canagliflozin—Asthenia—Levetiracetam—epilepsy syndrome	0.000106	0.000803	CcSEcCtD
Canagliflozin—Pruritus—Midazolam—epilepsy syndrome	0.000106	0.000802	CcSEcCtD
Canagliflozin—Constipation—Oxcarbazepine—epilepsy syndrome	0.000106	0.000799	CcSEcCtD
Canagliflozin—Urticaria—Felbamate—epilepsy syndrome	0.000105	0.000797	CcSEcCtD
Canagliflozin—Angiopathy—Pregabalin—epilepsy syndrome	0.000105	0.000795	CcSEcCtD
Canagliflozin—Urinary tract disorder—Gabapentin—epilepsy syndrome	0.000105	0.000794	CcSEcCtD
Canagliflozin—Abdominal pain—Felbamate—epilepsy syndrome	0.000105	0.000793	CcSEcCtD
Canagliflozin—Pruritus—Levetiracetam—epilepsy syndrome	0.000105	0.000792	CcSEcCtD
Canagliflozin—Urethral disorder—Gabapentin—epilepsy syndrome	0.000104	0.000788	CcSEcCtD
Canagliflozin—Pollakiuria—Topiramate—epilepsy syndrome	0.000103	0.000781	CcSEcCtD
Canagliflozin—Urticaria—Zonisamide—epilepsy syndrome	0.000103	0.00078	CcSEcCtD
Canagliflozin—Abdominal pain—Zonisamide—epilepsy syndrome	0.000103	0.000776	CcSEcCtD
Canagliflozin—Hypersensitivity—Vigabatrin—epilepsy syndrome	0.000103	0.000776	CcSEcCtD
Canagliflozin—Asthenia—Fosphenytoin—epilepsy syndrome	0.000103	0.000775	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Carbamazepine—epilepsy syndrome	0.000103	0.000775	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Clonazepam—epilepsy syndrome	0.000102	0.000774	CcSEcCtD
Canagliflozin—Fatigue—Carbamazepine—epilepsy syndrome	0.000102	0.000773	CcSEcCtD
Canagliflozin—Angioedema—Valproic Acid—epilepsy syndrome	0.000102	0.000771	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Topiramate—epilepsy syndrome	0.000102	0.000771	CcSEcCtD
Canagliflozin—Constipation—Carbamazepine—epilepsy syndrome	0.000102	0.000767	CcSEcCtD
Canagliflozin—Dizziness—Propofol—epilepsy syndrome	0.000101	0.000766	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Oxcarbazepine—epilepsy syndrome	0.000101	0.000764	CcSEcCtD
Canagliflozin—Pruritus—Fosphenytoin—epilepsy syndrome	0.000101	0.000764	CcSEcCtD
Canagliflozin—Hypersensitivity—Diazepam—epilepsy syndrome	0.000101	0.000764	CcSEcCtD
Canagliflozin—Malnutrition—Pregabalin—epilepsy syndrome	0.000101	0.000763	CcSEcCtD
Canagliflozin—Asthenia—Vigabatrin—epilepsy syndrome	0.0001	0.000755	CcSEcCtD
Canagliflozin—Urticaria—Clonazepam—epilepsy syndrome	9.95e-05	0.000752	CcSEcCtD
Canagliflozin—Dizziness—Midazolam—epilepsy syndrome	9.92e-05	0.000749	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Lamotrigine—epilepsy syndrome	9.91e-05	0.000749	CcSEcCtD
Canagliflozin—Abdominal pain—Clonazepam—epilepsy syndrome	9.9e-05	0.000748	CcSEcCtD
Canagliflozin—Fatigue—Lamotrigine—epilepsy syndrome	9.9e-05	0.000748	CcSEcCtD
Canagliflozin—Urticaria—Phenytoin—epilepsy syndrome	9.89e-05	0.000747	CcSEcCtD
Canagliflozin—Pruritus—Vigabatrin—epilepsy syndrome	9.86e-05	0.000745	CcSEcCtD
Canagliflozin—Asthenia—Diazepam—epilepsy syndrome	9.84e-05	0.000744	CcSEcCtD
Canagliflozin—Urticaria—Oxcarbazepine—epilepsy syndrome	9.83e-05	0.000743	CcSEcCtD
Canagliflozin—Constipation—Lamotrigine—epilepsy syndrome	9.82e-05	0.000741	CcSEcCtD
Canagliflozin—Nausea—Acetazolamide—epilepsy syndrome	9.81e-05	0.000741	CcSEcCtD
Canagliflozin—Dizziness—Levetiracetam—epilepsy syndrome	9.8e-05	0.00074	CcSEcCtD
Canagliflozin—Abdominal pain—Oxcarbazepine—epilepsy syndrome	9.78e-05	0.000739	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Carbamazepine—epilepsy syndrome	9.71e-05	0.000734	CcSEcCtD
Canagliflozin—Pruritus—Diazepam—epilepsy syndrome	9.71e-05	0.000733	CcSEcCtD
Canagliflozin—Urinary tract infection—Topiramate—epilepsy syndrome	9.7e-05	0.000732	CcSEcCtD
Canagliflozin—Rash—Propofol—epilepsy syndrome	9.67e-05	0.00073	CcSEcCtD
Canagliflozin—Dermatitis—Propofol—epilepsy syndrome	9.66e-05	0.00073	CcSEcCtD
Canagliflozin—Hypersensitivity—Zonisamide—epilepsy syndrome	9.58e-05	0.000723	CcSEcCtD
Canagliflozin—Asthenia—Felbamate—epilepsy syndrome	9.53e-05	0.00072	CcSEcCtD
Canagliflozin—Rash—Midazolam—epilepsy syndrome	9.46e-05	0.000714	CcSEcCtD
Canagliflozin—Dizziness—Fosphenytoin—epilepsy syndrome	9.45e-05	0.000714	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Valproic Acid—epilepsy syndrome	9.45e-05	0.000714	CcSEcCtD
Canagliflozin—Dermatitis—Midazolam—epilepsy syndrome	9.45e-05	0.000714	CcSEcCtD
Canagliflozin—Urticaria—Carbamazepine—epilepsy syndrome	9.44e-05	0.000713	CcSEcCtD
Canagliflozin—Pruritus—Felbamate—epilepsy syndrome	9.4e-05	0.00071	CcSEcCtD
Canagliflozin—Abdominal pain—Carbamazepine—epilepsy syndrome	9.39e-05	0.000709	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Lamotrigine—epilepsy syndrome	9.39e-05	0.000709	CcSEcCtD
Canagliflozin—Rash—Levetiracetam—epilepsy syndrome	9.34e-05	0.000705	CcSEcCtD
Canagliflozin—Dermatitis—Levetiracetam—epilepsy syndrome	9.33e-05	0.000705	CcSEcCtD
Canagliflozin—Asthenia—Zonisamide—epilepsy syndrome	9.33e-05	0.000704	CcSEcCtD
Canagliflozin—Dry mouth—Valproic Acid—epilepsy syndrome	9.31e-05	0.000703	CcSEcCtD
Canagliflozin—Erythema—Gabapentin—epilepsy syndrome	9.27e-05	0.0007	CcSEcCtD
Canagliflozin—Malnutrition—Gabapentin—epilepsy syndrome	9.27e-05	0.0007	CcSEcCtD
Canagliflozin—Angioedema—Pregabalin—epilepsy syndrome	9.23e-05	0.000697	CcSEcCtD
Canagliflozin—Hypersensitivity—Clonazepam—epilepsy syndrome	9.23e-05	0.000697	CcSEcCtD
Canagliflozin—Dizziness—Vigabatrin—epilepsy syndrome	9.22e-05	0.000696	CcSEcCtD
Canagliflozin—Pruritus—Zonisamide—epilepsy syndrome	9.2e-05	0.000695	CcSEcCtD
Canagliflozin—Hypersensitivity—Phenytoin—epilepsy syndrome	9.17e-05	0.000692	CcSEcCtD
Canagliflozin—Urticaria—Lamotrigine—epilepsy syndrome	9.12e-05	0.000689	CcSEcCtD
Canagliflozin—Hypersensitivity—Oxcarbazepine—epilepsy syndrome	9.12e-05	0.000689	CcSEcCtD
Canagliflozin—Nausea—Propofol—epilepsy syndrome	9.11e-05	0.000688	CcSEcCtD
Canagliflozin—Abdominal pain—Lamotrigine—epilepsy syndrome	9.07e-05	0.000685	CcSEcCtD
Canagliflozin—Dizziness—Diazepam—epilepsy syndrome	9.07e-05	0.000685	CcSEcCtD
Canagliflozin—Infection—Valproic Acid—epilepsy syndrome	9.06e-05	0.000684	CcSEcCtD
Canagliflozin—Syncope—Pregabalin—epilepsy syndrome	9.06e-05	0.000684	CcSEcCtD
Canagliflozin—Rash—Fosphenytoin—epilepsy syndrome	9.01e-05	0.000681	CcSEcCtD
Canagliflozin—Dermatitis—Fosphenytoin—epilepsy syndrome	9.01e-05	0.00068	CcSEcCtD
Canagliflozin—Asthenia—Clonazepam—epilepsy syndrome	8.99e-05	0.000679	CcSEcCtD
Canagliflozin—Nervous system disorder—Valproic Acid—epilepsy syndrome	8.95e-05	0.000676	CcSEcCtD
Canagliflozin—Asthenia—Phenytoin—epilepsy syndrome	8.93e-05	0.000674	CcSEcCtD
Canagliflozin—Nausea—Midazolam—epilepsy syndrome	8.91e-05	0.000673	CcSEcCtD
Canagliflozin—Loss of consciousness—Pregabalin—epilepsy syndrome	8.88e-05	0.000671	CcSEcCtD
Canagliflozin—Asthenia—Oxcarbazepine—epilepsy syndrome	8.88e-05	0.000671	CcSEcCtD
Canagliflozin—Pruritus—Clonazepam—epilepsy syndrome	8.86e-05	0.000669	CcSEcCtD
Canagliflozin—Skin disorder—Valproic Acid—epilepsy syndrome	8.86e-05	0.000669	CcSEcCtD
Canagliflozin—Urinary tract disorder—Topiramate—epilepsy syndrome	8.84e-05	0.000668	CcSEcCtD
Canagliflozin—Pruritus—Phenytoin—epilepsy syndrome	8.8e-05	0.000665	CcSEcCtD
Canagliflozin—Nausea—Levetiracetam—epilepsy syndrome	8.8e-05	0.000665	CcSEcCtD
Canagliflozin—Rash—Vigabatrin—epilepsy syndrome	8.79e-05	0.000664	CcSEcCtD
Canagliflozin—Dizziness—Felbamate—epilepsy syndrome	8.78e-05	0.000663	CcSEcCtD
Canagliflozin—Dermatitis—Vigabatrin—epilepsy syndrome	8.78e-05	0.000663	CcSEcCtD
Canagliflozin—Urethral disorder—Topiramate—epilepsy syndrome	8.78e-05	0.000663	CcSEcCtD
Canagliflozin—Pruritus—Oxcarbazepine—epilepsy syndrome	8.76e-05	0.000661	CcSEcCtD
Canagliflozin—Convulsion—Pregabalin—epilepsy syndrome	8.75e-05	0.000661	CcSEcCtD
Canagliflozin—Hypersensitivity—Carbamazepine—epilepsy syndrome	8.75e-05	0.000661	CcSEcCtD
Canagliflozin—Rash—Diazepam—epilepsy syndrome	8.65e-05	0.000653	CcSEcCtD
Canagliflozin—Dermatitis—Diazepam—epilepsy syndrome	8.64e-05	0.000653	CcSEcCtD
Canagliflozin—Dizziness—Zonisamide—epilepsy syndrome	8.6e-05	0.000649	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	8.54e-05	0.000645	CcSEcCtD
Canagliflozin—Hypotension—Valproic Acid—epilepsy syndrome	8.52e-05	0.000644	CcSEcCtD
Canagliflozin—Asthenia—Carbamazepine—epilepsy syndrome	8.52e-05	0.000644	CcSEcCtD
Canagliflozin—Nausea—Fosphenytoin—epilepsy syndrome	8.49e-05	0.000641	CcSEcCtD
Canagliflozin—Angioedema—Gabapentin—epilepsy syndrome	8.47e-05	0.000639	CcSEcCtD
Canagliflozin—Hypersensitivity—Lamotrigine—epilepsy syndrome	8.46e-05	0.000639	CcSEcCtD
Canagliflozin—Dry mouth—Pregabalin—epilepsy syndrome	8.41e-05	0.000635	CcSEcCtD
Canagliflozin—Pruritus—Carbamazepine—epilepsy syndrome	8.4e-05	0.000635	CcSEcCtD
Canagliflozin—Rash—Felbamate—epilepsy syndrome	8.37e-05	0.000632	CcSEcCtD
Canagliflozin—Dermatitis—Felbamate—epilepsy syndrome	8.37e-05	0.000632	CcSEcCtD
Canagliflozin—Syncope—Gabapentin—epilepsy syndrome	8.31e-05	0.000628	CcSEcCtD
Canagliflozin—Dizziness—Clonazepam—epilepsy syndrome	8.28e-05	0.000626	CcSEcCtD
Canagliflozin—Nausea—Vigabatrin—epilepsy syndrome	8.28e-05	0.000625	CcSEcCtD
Canagliflozin—Asthenia—Lamotrigine—epilepsy syndrome	8.24e-05	0.000622	CcSEcCtD
Canagliflozin—Dizziness—Phenytoin—epilepsy syndrome	8.23e-05	0.000622	CcSEcCtD
Canagliflozin—Rash—Zonisamide—epilepsy syndrome	8.2e-05	0.000619	CcSEcCtD
Canagliflozin—Infection—Pregabalin—epilepsy syndrome	8.19e-05	0.000619	CcSEcCtD
Canagliflozin—Dermatitis—Zonisamide—epilepsy syndrome	8.19e-05	0.000618	CcSEcCtD
Canagliflozin—Dizziness—Oxcarbazepine—epilepsy syndrome	8.19e-05	0.000618	CcSEcCtD
Canagliflozin—Nausea—Diazepam—epilepsy syndrome	8.15e-05	0.000616	CcSEcCtD
Canagliflozin—Loss of consciousness—Gabapentin—epilepsy syndrome	8.14e-05	0.000615	CcSEcCtD
Canagliflozin—Angiopathy—Topiramate—epilepsy syndrome	8.12e-05	0.000614	CcSEcCtD
Canagliflozin—Pruritus—Lamotrigine—epilepsy syndrome	8.12e-05	0.000613	CcSEcCtD
Canagliflozin—Shock—Pregabalin—epilepsy syndrome	8.11e-05	0.000613	CcSEcCtD
Canagliflozin—Nervous system disorder—Pregabalin—epilepsy syndrome	8.09e-05	0.000611	CcSEcCtD
Canagliflozin—Convulsion—Gabapentin—epilepsy syndrome	8.03e-05	0.000606	CcSEcCtD
Canagliflozin—Skin disorder—Pregabalin—epilepsy syndrome	8.01e-05	0.000605	CcSEcCtD
Canagliflozin—Rash—Clonazepam—epilepsy syndrome	7.9e-05	0.000597	CcSEcCtD
Canagliflozin—Dermatitis—Clonazepam—epilepsy syndrome	7.89e-05	0.000596	CcSEcCtD
Canagliflozin—Nausea—Felbamate—epilepsy syndrome	7.89e-05	0.000596	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	7.88e-05	0.000595	CcSEcCtD
Canagliflozin—Fatigue—Valproic Acid—epilepsy syndrome	7.86e-05	0.000594	CcSEcCtD
Canagliflozin—Dizziness—Carbamazepine—epilepsy syndrome	7.85e-05	0.000593	CcSEcCtD
Canagliflozin—Rash—Phenytoin—epilepsy syndrome	7.85e-05	0.000593	CcSEcCtD
Canagliflozin—Dermatitis—Phenytoin—epilepsy syndrome	7.84e-05	0.000592	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	7.83e-05	0.000592	CcSEcCtD
Canagliflozin—Rash—Oxcarbazepine—epilepsy syndrome	7.8e-05	0.000589	CcSEcCtD
Canagliflozin—Constipation—Valproic Acid—epilepsy syndrome	7.8e-05	0.000589	CcSEcCtD
Canagliflozin—Dermatitis—Oxcarbazepine—epilepsy syndrome	7.8e-05	0.000589	CcSEcCtD
Canagliflozin—Malnutrition—Topiramate—epilepsy syndrome	7.8e-05	0.000589	CcSEcCtD
Canagliflozin—Erythema—Topiramate—epilepsy syndrome	7.8e-05	0.000589	CcSEcCtD
Canagliflozin—Nausea—Zonisamide—epilepsy syndrome	7.72e-05	0.000583	CcSEcCtD
Canagliflozin—Dry mouth—Gabapentin—epilepsy syndrome	7.71e-05	0.000583	CcSEcCtD
Canagliflozin—Hypotension—Pregabalin—epilepsy syndrome	7.71e-05	0.000582	CcSEcCtD
Canagliflozin—Dizziness—Lamotrigine—epilepsy syndrome	7.59e-05	0.000573	CcSEcCtD
Canagliflozin—Infection—Gabapentin—epilepsy syndrome	7.51e-05	0.000567	CcSEcCtD
Canagliflozin—Rash—Carbamazepine—epilepsy syndrome	7.49e-05	0.000566	CcSEcCtD
Canagliflozin—Dermatitis—Carbamazepine—epilepsy syndrome	7.48e-05	0.000565	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	7.46e-05	0.000563	CcSEcCtD
Canagliflozin—Nausea—Clonazepam—epilepsy syndrome	7.44e-05	0.000562	CcSEcCtD
Canagliflozin—Shock—Gabapentin—epilepsy syndrome	7.44e-05	0.000562	CcSEcCtD
Canagliflozin—Nervous system disorder—Gabapentin—epilepsy syndrome	7.42e-05	0.00056	CcSEcCtD
Canagliflozin—Nausea—Phenytoin—epilepsy syndrome	7.39e-05	0.000558	CcSEcCtD
Canagliflozin—Nausea—Oxcarbazepine—epilepsy syndrome	7.35e-05	0.000555	CcSEcCtD
Canagliflozin—Skin disorder—Gabapentin—epilepsy syndrome	7.35e-05	0.000555	CcSEcCtD
Canagliflozin—Urticaria—Valproic Acid—epilepsy syndrome	7.25e-05	0.000547	CcSEcCtD
Canagliflozin—Rash—Lamotrigine—epilepsy syndrome	7.24e-05	0.000547	CcSEcCtD
Canagliflozin—Dermatitis—Lamotrigine—epilepsy syndrome	7.23e-05	0.000546	CcSEcCtD
Canagliflozin—Abdominal pain—Valproic Acid—epilepsy syndrome	7.21e-05	0.000545	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	7.12e-05	0.000538	CcSEcCtD
Canagliflozin—Fatigue—Pregabalin—epilepsy syndrome	7.11e-05	0.000537	CcSEcCtD
Canagliflozin—Hypotension—Gabapentin—epilepsy syndrome	7.07e-05	0.000534	CcSEcCtD
Canagliflozin—Nausea—Carbamazepine—epilepsy syndrome	7.06e-05	0.000533	CcSEcCtD
Canagliflozin—Constipation—Pregabalin—epilepsy syndrome	7.05e-05	0.000533	CcSEcCtD
Canagliflozin—Syncope—Topiramate—epilepsy syndrome	6.99e-05	0.000528	CcSEcCtD
Canagliflozin—Loss of consciousness—Topiramate—epilepsy syndrome	6.85e-05	0.000518	CcSEcCtD
Canagliflozin—Nausea—Lamotrigine—epilepsy syndrome	6.82e-05	0.000515	CcSEcCtD
Canagliflozin—Convulsion—Topiramate—epilepsy syndrome	6.75e-05	0.00051	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Pregabalin—epilepsy syndrome	6.74e-05	0.000509	CcSEcCtD
Canagliflozin—Hypersensitivity—Valproic Acid—epilepsy syndrome	6.72e-05	0.000508	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	6.59e-05	0.000498	CcSEcCtD
Canagliflozin—Urticaria—Pregabalin—epilepsy syndrome	6.55e-05	0.000495	CcSEcCtD
Canagliflozin—Asthenia—Valproic Acid—epilepsy syndrome	6.54e-05	0.000494	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	6.53e-05	0.000493	CcSEcCtD
Canagliflozin—Fatigue—Gabapentin—epilepsy syndrome	6.52e-05	0.000492	CcSEcCtD
Canagliflozin—Abdominal pain—Pregabalin—epilepsy syndrome	6.52e-05	0.000492	CcSEcCtD
Canagliflozin—Dry mouth—Topiramate—epilepsy syndrome	6.49e-05	0.00049	CcSEcCtD
Canagliflozin—Constipation—Gabapentin—epilepsy syndrome	6.47e-05	0.000488	CcSEcCtD
Canagliflozin—Pruritus—Valproic Acid—epilepsy syndrome	6.45e-05	0.000487	CcSEcCtD
Canagliflozin—Infection—Topiramate—epilepsy syndrome	6.32e-05	0.000477	CcSEcCtD
Canagliflozin—Shock—Topiramate—epilepsy syndrome	6.26e-05	0.000473	CcSEcCtD
Canagliflozin—Nervous system disorder—Topiramate—epilepsy syndrome	6.24e-05	0.000471	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Gabapentin—epilepsy syndrome	6.18e-05	0.000467	CcSEcCtD
Canagliflozin—Skin disorder—Topiramate—epilepsy syndrome	6.18e-05	0.000467	CcSEcCtD
Canagliflozin—Hypersensitivity—Pregabalin—epilepsy syndrome	6.08e-05	0.000459	CcSEcCtD
Canagliflozin—Dizziness—Valproic Acid—epilepsy syndrome	6.03e-05	0.000456	CcSEcCtD
Canagliflozin—Urticaria—Gabapentin—epilepsy syndrome	6.01e-05	0.000454	CcSEcCtD
Canagliflozin—Abdominal pain—Gabapentin—epilepsy syndrome	5.98e-05	0.000452	CcSEcCtD
Canagliflozin—Hypotension—Topiramate—epilepsy syndrome	5.94e-05	0.000449	CcSEcCtD
Canagliflozin—Asthenia—Pregabalin—epilepsy syndrome	5.92e-05	0.000447	CcSEcCtD
Canagliflozin—Pruritus—Pregabalin—epilepsy syndrome	5.83e-05	0.000441	CcSEcCtD
Canagliflozin—Rash—Valproic Acid—epilepsy syndrome	5.75e-05	0.000434	CcSEcCtD
Canagliflozin—Dermatitis—Valproic Acid—epilepsy syndrome	5.75e-05	0.000434	CcSEcCtD
Canagliflozin—Hypersensitivity—Gabapentin—epilepsy syndrome	5.57e-05	0.000421	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Topiramate—epilepsy syndrome	5.49e-05	0.000415	CcSEcCtD
Canagliflozin—Fatigue—Topiramate—epilepsy syndrome	5.49e-05	0.000414	CcSEcCtD
Canagliflozin—Dizziness—Pregabalin—epilepsy syndrome	5.45e-05	0.000412	CcSEcCtD
Canagliflozin—Constipation—Topiramate—epilepsy syndrome	5.44e-05	0.000411	CcSEcCtD
Canagliflozin—Asthenia—Gabapentin—epilepsy syndrome	5.43e-05	0.00041	CcSEcCtD
Canagliflozin—Nausea—Valproic Acid—epilepsy syndrome	5.42e-05	0.000409	CcSEcCtD
Canagliflozin—Pruritus—Gabapentin—epilepsy syndrome	5.35e-05	0.000404	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Topiramate—epilepsy syndrome	5.2e-05	0.000393	CcSEcCtD
Canagliflozin—Rash—Pregabalin—epilepsy syndrome	5.2e-05	0.000393	CcSEcCtD
Canagliflozin—Dermatitis—Pregabalin—epilepsy syndrome	5.19e-05	0.000392	CcSEcCtD
Canagliflozin—Urticaria—Topiramate—epilepsy syndrome	5.05e-05	0.000382	CcSEcCtD
Canagliflozin—Abdominal pain—Topiramate—epilepsy syndrome	5.03e-05	0.00038	CcSEcCtD
Canagliflozin—Dizziness—Gabapentin—epilepsy syndrome	5e-05	0.000378	CcSEcCtD
Canagliflozin—Nausea—Pregabalin—epilepsy syndrome	4.9e-05	0.00037	CcSEcCtD
Canagliflozin—Rash—Gabapentin—epilepsy syndrome	4.77e-05	0.00036	CcSEcCtD
Canagliflozin—Dermatitis—Gabapentin—epilepsy syndrome	4.76e-05	0.00036	CcSEcCtD
Canagliflozin—Hypersensitivity—Topiramate—epilepsy syndrome	4.69e-05	0.000354	CcSEcCtD
Canagliflozin—Asthenia—Topiramate—epilepsy syndrome	4.56e-05	0.000345	CcSEcCtD
Canagliflozin—Pruritus—Topiramate—epilepsy syndrome	4.5e-05	0.00034	CcSEcCtD
Canagliflozin—Nausea—Gabapentin—epilepsy syndrome	4.49e-05	0.000339	CcSEcCtD
Canagliflozin—Dizziness—Topiramate—epilepsy syndrome	4.21e-05	0.000318	CcSEcCtD
Canagliflozin—Rash—Topiramate—epilepsy syndrome	4.01e-05	0.000303	CcSEcCtD
Canagliflozin—Dermatitis—Topiramate—epilepsy syndrome	4.01e-05	0.000303	CcSEcCtD
Canagliflozin—Nausea—Topiramate—epilepsy syndrome	3.78e-05	0.000285	CcSEcCtD
Canagliflozin—ABCB1—Metabolism—NHLRC1—epilepsy syndrome	1.22e-05	0.000159	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—EPM2A—epilepsy syndrome	1.22e-05	0.000159	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—COX3—epilepsy syndrome	1.22e-05	0.000159	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CHRM3—epilepsy syndrome	1.21e-05	0.000157	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—KCNJ11—epilepsy syndrome	1.21e-05	0.000157	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—SLC6A1—epilepsy syndrome	1.2e-05	0.000157	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—ITGA2—epilepsy syndrome	1.2e-05	0.000157	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—TNF—epilepsy syndrome	1.19e-05	0.000155	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—AQP4—epilepsy syndrome	1.18e-05	0.000154	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—SLC1A3—epilepsy syndrome	1.18e-05	0.000154	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PTGS2—epilepsy syndrome	1.18e-05	0.000153	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PTGS2—epilepsy syndrome	1.18e-05	0.000153	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—epilepsy syndrome	1.17e-05	0.000152	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—PRKCB—epilepsy syndrome	1.16e-05	0.000151	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—SLCO1A2—epilepsy syndrome	1.15e-05	0.00015	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—SLC6A8—epilepsy syndrome	1.15e-05	0.00015	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PFKL—epilepsy syndrome	1.15e-05	0.00015	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CACNA2D2—epilepsy syndrome	1.15e-05	0.00015	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—KCNB1—epilepsy syndrome	1.15e-05	0.00015	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—POMC—epilepsy syndrome	1.14e-05	0.000148	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—SRC—epilepsy syndrome	1.14e-05	0.000148	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—SRC—epilepsy syndrome	1.14e-05	0.000148	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—TNF—epilepsy syndrome	1.14e-05	0.000148	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CA4—epilepsy syndrome	1.14e-05	0.000148	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—QDPR—epilepsy syndrome	1.14e-05	0.000148	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—ABCC2—epilepsy syndrome	1.13e-05	0.000148	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—CYP2C19—epilepsy syndrome	1.13e-05	0.000147	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—AGT—epilepsy syndrome	1.13e-05	0.000147	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—CYP11A1—epilepsy syndrome	1.12e-05	0.000146	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—APOE—epilepsy syndrome	1.1e-05	0.000144	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—ABCG2—epilepsy syndrome	1.1e-05	0.000143	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CA13—epilepsy syndrome	1.09e-05	0.000141	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—ATP2A2—epilepsy syndrome	1.07e-05	0.00014	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—COX3—epilepsy syndrome	1.07e-05	0.000139	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—ADRA2A—epilepsy syndrome	1.06e-05	0.000138	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—UPB1—epilepsy syndrome	1.06e-05	0.000138	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ATIC—epilepsy syndrome	1.06e-05	0.000138	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—NEU1—epilepsy syndrome	1.06e-05	0.000138	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—SLC6A1—epilepsy syndrome	1.05e-05	0.000137	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PLAT—epilepsy syndrome	1.05e-05	0.000137	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—ALB—epilepsy syndrome	1.04e-05	0.000135	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—epilepsy syndrome	1.02e-05	0.000133	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—HSD17B4—epilepsy syndrome	1.02e-05	0.000132	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PFKL—epilepsy syndrome	1.01e-05	0.000132	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CACNA2D2—epilepsy syndrome	1.01e-05	0.000132	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—SLCO1A2—epilepsy syndrome	1.01e-05	0.000132	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—KCNB1—epilepsy syndrome	1.01e-05	0.000132	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—SLC6A8—epilepsy syndrome	1.01e-05	0.000132	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—NOS1—epilepsy syndrome	9.91e-06	0.000129	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ABCG2—epilepsy syndrome	9.85e-06	0.000128	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GBE1—epilepsy syndrome	9.82e-06	0.000128	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PPP1R3C—epilepsy syndrome	9.82e-06	0.000128	CbGpPWpGaD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—AKT1—epilepsy syndrome	9.76e-06	0.000127	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—ABCG2—epilepsy syndrome	9.65e-06	0.000126	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CYP2C19—epilepsy syndrome	9.6e-06	0.000125	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—BCHE—epilepsy syndrome	9.6e-06	0.000125	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CYP11A1—epilepsy syndrome	9.54e-06	0.000124	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	9.47e-06	0.000123	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—ATP2A2—epilepsy syndrome	9.4e-06	0.000122	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—AKT3—epilepsy syndrome	9.28e-06	0.000121	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—UPB1—epilepsy syndrome	9.25e-06	0.00012	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ATIC—epilepsy syndrome	9.25e-06	0.00012	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—NEU1—epilepsy syndrome	9.25e-06	0.00012	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ASAH1—epilepsy syndrome	9.23e-06	0.00012	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—FGF2—epilepsy syndrome	9.2e-06	0.00012	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PLAUR—epilepsy syndrome	9.17e-06	0.000119	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—PLAT—epilepsy syndrome	9.12e-06	0.000119	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PTGS2—epilepsy syndrome	9.09e-06	0.000118	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—STXBP1—epilepsy syndrome	8.98e-06	0.000117	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—HSD17B4—epilepsy syndrome	8.91e-06	0.000116	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—NT5E—epilepsy syndrome	8.75e-06	0.000114	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ALAD—epilepsy syndrome	8.75e-06	0.000114	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—epilepsy syndrome	8.74e-06	0.000114	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—SLC2A1—epilepsy syndrome	8.7e-06	0.000113	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	8.64e-06	0.000112	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CYP2D6—epilepsy syndrome	8.61e-06	0.000112	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GBE1—epilepsy syndrome	8.6e-06	0.000112	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PPP1R3C—epilepsy syndrome	8.6e-06	0.000112	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—CDC42—epilepsy syndrome	8.47e-06	0.00011	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ALDH7A1—epilepsy syndrome	8.35e-06	0.000109	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CACNA1A—epilepsy syndrome	8.35e-06	0.000109	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—epilepsy syndrome	8.3e-06	0.000108	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—FAR1—epilepsy syndrome	8.22e-06	0.000107	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GLUD1—epilepsy syndrome	8.22e-06	0.000107	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ADK—epilepsy syndrome	8.22e-06	0.000107	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—L2HGDH—epilepsy syndrome	8.22e-06	0.000107	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PDXK—epilepsy syndrome	8.22e-06	0.000107	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CERS1—epilepsy syndrome	8.22e-06	0.000107	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ADRA2A—epilepsy syndrome	8.2e-06	0.000107	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ST3GAL3—epilepsy syndrome	8.17e-06	0.000106	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—BCHE—epilepsy syndrome	8.16e-06	0.000106	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ASAH1—epilepsy syndrome	8.09e-06	0.000105	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—ALB—epilepsy syndrome	8.01e-06	0.000104	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ADSL—epilepsy syndrome	8e-06	0.000104	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—PLAT—epilepsy syndrome	7.99e-06	0.000104	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—STXBP1—epilepsy syndrome	7.87e-06	0.000102	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GLUL—epilepsy syndrome	7.85e-06	0.000102	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—SLC2A1—epilepsy syndrome	7.79e-06	0.000101	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—epilepsy syndrome	7.7e-06	0.0001	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CACNA1D—epilepsy syndrome	7.7e-06	0.0001	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PLCB1—epilepsy syndrome	7.7e-06	0.0001	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—TH—epilepsy syndrome	7.67e-06	9.99e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—NT5E—epilepsy syndrome	7.67e-06	9.98e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ALAD—epilepsy syndrome	7.67e-06	9.98e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—SLC2A1—epilepsy syndrome	7.63e-06	9.93e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	7.55e-06	9.84e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—FYN—epilepsy syndrome	7.54e-06	9.81e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PNPO—epilepsy syndrome	7.52e-06	9.79e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—EPM2A—epilepsy syndrome	7.52e-06	9.79e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NHLRC1—epilepsy syndrome	7.52e-06	9.79e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GAMT—epilepsy syndrome	7.52e-06	9.79e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—epilepsy syndrome	7.48e-06	9.74e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CACNA1A—epilepsy syndrome	7.31e-06	9.52e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ALDH7A1—epilepsy syndrome	7.31e-06	9.52e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—YWHAZ—epilepsy syndrome	7.25e-06	9.43e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—TXNRD1—epilepsy syndrome	7.21e-06	9.38e-05	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—HMOX1—epilepsy syndrome	7.16e-06	9.32e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ST3GAL3—epilepsy syndrome	7.16e-06	9.32e-05	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—AVP—epilepsy syndrome	7.1e-06	9.24e-05	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—AKT1—epilepsy syndrome	7.07e-06	9.2e-05	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—AKT1—epilepsy syndrome	7.07e-06	9.2e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ADSL—epilepsy syndrome	7.01e-06	9.13e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—AQP1—epilepsy syndrome	7e-06	9.11e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—QDPR—epilepsy syndrome	6.99e-06	9.11e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CA4—epilepsy syndrome	6.99e-06	9.11e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—POMC—epilepsy syndrome	6.97e-06	9.08e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GLUL—epilepsy syndrome	6.88e-06	8.95e-05	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—ABCB1—epilepsy syndrome	6.87e-06	8.95e-05	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—SRC—epilepsy syndrome	6.82e-06	8.88e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CACNA1D—epilepsy syndrome	6.75e-06	8.79e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—GPX1—epilepsy syndrome	6.72e-06	8.75e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—epilepsy syndrome	6.71e-06	8.74e-05	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—VEGFA—epilepsy syndrome	6.64e-06	8.64e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—COX3—epilepsy syndrome	6.58e-06	8.56e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—epilepsy syndrome	6.54e-06	8.51e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PLAU—epilepsy syndrome	6.43e-06	8.37e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—HMOX1—epilepsy syndrome	6.4e-06	8.34e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CHRM3—epilepsy syndrome	6.33e-06	8.24e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—KCNJ11—epilepsy syndrome	6.33e-06	8.24e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CAT—epilepsy syndrome	6.32e-06	8.23e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—TXNRD1—epilepsy syndrome	6.31e-06	8.22e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—HMOX1—epilepsy syndrome	6.27e-06	8.17e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SLCO1A2—epilepsy syndrome	6.23e-06	8.12e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CACNA2D2—epilepsy syndrome	6.23e-06	8.12e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PFKL—epilepsy syndrome	6.23e-06	8.12e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—KCNB1—epilepsy syndrome	6.23e-06	8.12e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SLC6A8—epilepsy syndrome	6.23e-06	8.12e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—AVP—epilepsy syndrome	6.22e-06	8.09e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ABCB1—epilepsy syndrome	6.15e-06	8e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—AQP1—epilepsy syndrome	6.13e-06	7.98e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PRKCB—epilepsy syndrome	5.98e-06	7.79e-05	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—AKT1—epilepsy syndrome	5.92e-06	7.7e-05	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—AKT1—epilepsy syndrome	5.92e-06	7.7e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—NOS2—epilepsy syndrome	5.91e-06	7.69e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—AGT—epilepsy syndrome	5.89e-06	7.67e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—APOE—epilepsy syndrome	5.77e-06	7.52e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GPX1—epilepsy syndrome	5.72e-06	7.44e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NEU1—epilepsy syndrome	5.7e-06	7.42e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—UPB1—epilepsy syndrome	5.7e-06	7.42e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ATIC—epilepsy syndrome	5.7e-06	7.42e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—epilepsy syndrome	5.6e-06	7.3e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CHRM3—epilepsy syndrome	5.54e-06	7.22e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—KCNJ11—epilepsy syndrome	5.54e-06	7.22e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HSD17B4—epilepsy syndrome	5.49e-06	7.14e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PPP1R3C—epilepsy syndrome	5.3e-06	6.9e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GBE1—epilepsy syndrome	5.3e-06	6.9e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ABCG2—epilepsy syndrome	5.16e-06	6.72e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP2C19—epilepsy syndrome	5.03e-06	6.54e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—AGT—epilepsy syndrome	5.01e-06	6.53e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP11A1—epilepsy syndrome	4.99e-06	6.5e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ASAH1—epilepsy syndrome	4.98e-06	6.49e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	4.96e-06	6.46e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—APOE—epilepsy syndrome	4.91e-06	6.39e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—STXBP1—epilepsy syndrome	4.85e-06	6.31e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NT5E—epilepsy syndrome	4.72e-06	6.15e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ALAD—epilepsy syndrome	4.72e-06	6.15e-05	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—AKT1—epilepsy syndrome	4.57e-06	5.95e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ABCG2—epilepsy syndrome	4.52e-06	5.88e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP2D6—epilepsy syndrome	4.51e-06	5.87e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ALDH7A1—epilepsy syndrome	4.51e-06	5.87e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CACNA1A—epilepsy syndrome	4.51e-06	5.87e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ST3GAL3—epilepsy syndrome	4.41e-06	5.74e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP2C19—epilepsy syndrome	4.4e-06	5.73e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP11A1—epilepsy syndrome	4.38e-06	5.7e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ADSL—epilepsy syndrome	4.32e-06	5.63e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ADRA2A—epilepsy syndrome	4.29e-06	5.59e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—BCHE—epilepsy syndrome	4.27e-06	5.56e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GLUL—epilepsy syndrome	4.24e-06	5.52e-05	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—AKT1—epilepsy syndrome	4.24e-06	5.52e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—POMC—epilepsy syndrome	4.22e-06	5.49e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—epilepsy syndrome	4.17e-06	5.43e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CACNA1D—epilepsy syndrome	4.16e-06	5.41e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—SLC2A1—epilepsy syndrome	4.08e-06	5.31e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PLCB1—epilepsy syndrome	4.03e-06	5.25e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—TH—epilepsy syndrome	4.02e-06	5.23e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	3.96e-06	5.15e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP2D6—epilepsy syndrome	3.95e-06	5.14e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—TXNRD1—epilepsy syndrome	3.89e-06	5.06e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ALB—epilepsy syndrome	3.85e-06	5.01e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—AQP1—epilepsy syndrome	3.78e-06	4.92e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—ALB—epilepsy syndrome	3.77e-06	4.9e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ADRA2A—epilepsy syndrome	3.76e-06	4.9e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—BCHE—epilepsy syndrome	3.74e-06	4.88e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—SLC2A1—epilepsy syndrome	3.57e-06	4.65e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PLCB1—epilepsy syndrome	3.53e-06	4.6e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—TH—epilepsy syndrome	3.52e-06	4.58e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—SRC—epilepsy syndrome	3.51e-06	4.58e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—VEGFA—epilepsy syndrome	3.42e-06	4.46e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—KCNJ11—epilepsy syndrome	3.42e-06	4.45e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CHRM3—epilepsy syndrome	3.42e-06	4.45e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PTGS2—epilepsy syndrome	3.36e-06	4.38e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—HMOX1—epilepsy syndrome	3.35e-06	4.37e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CAT—epilepsy syndrome	3.31e-06	4.31e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ABCB1—epilepsy syndrome	3.22e-06	4.19e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GPX1—epilepsy syndrome	2.99e-06	3.9e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—HMOX1—epilepsy syndrome	2.94e-06	3.83e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CAT—epilepsy syndrome	2.9e-06	3.77e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ABCG2—epilepsy syndrome	2.78e-06	3.62e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP2C19—epilepsy syndrome	2.71e-06	3.53e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP11A1—epilepsy syndrome	2.7e-06	3.51e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—AGT—epilepsy syndrome	2.62e-06	3.42e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GPX1—epilepsy syndrome	2.62e-06	3.41e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—APOE—epilepsy syndrome	2.57e-06	3.35e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP2D6—epilepsy syndrome	2.43e-06	3.17e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ADRA2A—epilepsy syndrome	2.32e-06	3.02e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—BCHE—epilepsy syndrome	2.31e-06	3e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—AGT—epilepsy syndrome	2.3e-06	2.99e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—APOE—epilepsy syndrome	2.25e-06	2.93e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—POMC—epilepsy syndrome	2.21e-06	2.88e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SLC2A1—epilepsy syndrome	2.2e-06	2.87e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—AKT1—epilepsy syndrome	2.18e-06	2.84e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PLCB1—epilepsy syndrome	2.18e-06	2.83e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—TH—epilepsy syndrome	2.17e-06	2.82e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—POMC—epilepsy syndrome	1.94e-06	2.52e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HMOX1—epilepsy syndrome	1.81e-06	2.36e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CAT—epilepsy syndrome	1.79e-06	2.33e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ALB—epilepsy syndrome	1.76e-06	2.3e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PTGS2—epilepsy syndrome	1.76e-06	2.29e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ABCB1—epilepsy syndrome	1.74e-06	2.26e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—AKT1—epilepsy syndrome	1.69e-06	2.2e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GPX1—epilepsy syndrome	1.62e-06	2.1e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PTGS2—epilepsy syndrome	1.54e-06	2.01e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—AGT—epilepsy syndrome	1.42e-06	1.84e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—APOE—epilepsy syndrome	1.39e-06	1.81e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—POMC—epilepsy syndrome	1.19e-06	1.55e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ALB—epilepsy syndrome	1.09e-06	1.42e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PTGS2—epilepsy syndrome	9.51e-07	1.24e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—AKT1—epilepsy syndrome	8.85e-07	1.15e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—AKT1—epilepsy syndrome	7.76e-07	1.01e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—AKT1—epilepsy syndrome	4.78e-07	6.22e-06	CbGpPWpGaD
